NEW YORK, May 1, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ) (Intercept), a clinical stage biopharmaceutical company focused on the development and commercialization of novel bile acid therapeutics to treat chronic liver and intestinal diseases, today announced that it will report first quarter 2014 financial results after the NASDAQ Market closes on Wednesday, May 7, 2014. Intercept management will conduct a conference call and audio webcast on May 7, 2014 at 4:30 p.m. ET to discuss these results and provide an update on the company's business.
Mark Pruzanski, M.D., President and Chief Executive Officer, will also be presenting at the following upcoming investor conferences:
- Deutsche Bank 39th Annual Health Care Conference at 2:50 p.m. ET on Thursday, May 8, 2014, in Boston
- Bank of America 2014 Health Care Conference at 2:20 p.m. PT on Wednesday, May 14, 2014 in Las Vegas
- Jefferies 2014 Global Health Care Conference at 4:00 p.m. ET on Tuesday, June 3, 2014 in New York
Dial-in information for the May 7 conference call and live webcasts for all of these events will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com . Archived webcasts will be available on Intercept's website for approximately two weeks.
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and intestinal diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH), portal hypertension, bile acid diarrhea and primary sclerosing cholangitis (PSC). OCA has met the primary efficacy endpoint in five placebo-controlled clinical trials, including the recently completed POISE Phase 3 clinical trial in patients with PBC and two Phase 2 clinical trials in NASH and nonalcoholic fatty liver disease. OCA has received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan and China, where it has out-licensed the product candidate to Dainippon Sumitomo Pharma (DSP). For more information about Intercept, please visit the Company's website at: www.interceptpharma.com .
For more information about Intercept, please contact Barbara Duncan or Senthil Sundaram, both of Intercept Pharmaceuticals at 1-646-747-1000 Media inquiries: Investor inquiries:
